INTRODUCTION AND OBJECTIVES:
The mammalian target of rapamycin (mTOR) pathway is known to play an important role in oncology. However, its role in prostate cancer (PCa) has not been fully understood. The aim of the study was to evaluate the expression of mTOR, phosphorylated-mTOR (p-mTOR) and Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) in patients with PCa using tissue microarray (TMA) technique and to assess their correlation with clinico-pathological parameters and outcome.
METHODS: Tissue samples from 115 consecutive patients who underwent radical prostatectomy were constructed to a TMA. In every case four localisations were included: A) from the tumour center, B) malignant border of the tumour, C) tumour adjacent benign tissue and D) tumour-distant benign prostatic tissue. Expression scores were strati ed according to their respective median immune reactive score 0-12 into 'weak' (< median) and 'strong' (¼ median). A meta-analysis of studies from Medline, Scopus and Web of knowledge were retrieved to investigate the association between biochemical recurrence and mTOR pathways immunostaining.
RESULTS: Expression scores of mTOR, in A, B, C and D were 9.1, 8.8, 5.0 and 6.8 (p<0.01), p-mTOR scores were 7.4, 7.2, 2.0, 4.6 (p<0.01) while 4E-BP1 scores were 8.0, 7.6, 2.6 and 3.1 (p<0.01), respectively. We observed lower p-mTOR scores in A samples (6.3 and 7.9; p¼0.01) in locally advanced vs. organ con ned PCa. Overall, 523 studies were identi ed from the databases and relevant references and 4 studies were added to our cohort for the meta-analysis. We found that 'strong' staining of p-mTOR was associated with lower risk of BCR (biochemical recurrence) (risk ratio [RR]¼ 0.57; p¼0.002) while no association for mTOR (RR¼ 0.70; p¼0.13) or 4E-BP1 (RR¼ 0.86; p¼0.53) was found (Figure 1) . CONCLUSIONS: All 3 markers showed local gradients of expression in PCa tissue. Moreover, expression characteristics suggest disorders in the mTOR system. In particular p-mTOR was associated with more aggressive PCa and could be clinically useful as a prognostic marker for BCR and to assess their local diversity as well as their correlation with clinico-pathological parameters.
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MP29-04 COMBINATION THERAPY WITH EPI-002 AND IONIZING RADIATION FOR CASTRATION-RESISTANT PROSTATE CANCER
Yusuke Ito*, C. Adriana Banuelos, Marianne D. Sadar, Vancouver, Canada INTRODUCTION AND OBJECTIVES: Targeted radiotherapy with radium 223 dichloride for metastatic castration resistant prostate cancer (mCRPC) increases overall survival (OS) of patients with bone metastases by approximately 3 months. Emerging evidence supports that androgen receptor (AR) signaling regulates DNA repair in prostate cancer. Thus a combination approach using AR modulating drugs with radiation could be a promising option for the treatment of mCRPC. All currently approved AR modulating drugs, such as enzalutamide and abiraterone, either directly or indirectly target the AR C-terminus ligandbinding domain (LBD). Such drugs are often unsuccessful due to the emergence of AR splice variants (ARV-7, ARv567es) that are constitutively active and lack a LBD. EPI-002 is a first-in-class AR antagonist that binds to its N-terminus domain to target both full-length AR and AR splice variants such as AR-V7. Here we present data to support that a combination of EPI-002 and ionizing radiation has beneficial effects in vitro.
METHODS: Combination therapy using EPI-002 and ionizing radiation were evaluated in vitro using LNCaP95 human prostate cancer cells. This cell line is androgen-independent, expresses full-length AR and AR-V7, and is resistant to enzalutamide and other antiandrogens. Proliferation was evaluated using BrdU incorporation and colony formation assays. The effects of monotherapy and combination therapy on cell cycle and DNA damage were analysed using FACS and Western blot.
RESULTS: Ionizing radiation increased the expression of fulllength AR and AR splice variants and their gene targets, PSA and TMPRSS2. EPI-002 induced G1 cell cycle arrest whereas radiation induced G2/M cell cycle arrest. FACS analysis showed dose-dependent blocking of BrdU incorporation and more accumulation of gammaH2AX in S phase cells in the combination therapy at higher doses of ionizing radiation compared to monotherapy. Combination therapy suggests a synergistic inhibitory effect on proliferation of LNCaP95 cells.
CONCLUSIONS: Consistent with previous reports, radiation increased expression of full-length AR expression. Building on these data, here we show for the first time that radiation also increases the expression of AR splice variants thereby implying a possible e366 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 
